Trials
Search / Trial NCT05646576

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Launched by MASSACHUSETTS GENERAL HOSPITAL · Dec 2, 2022

Apply for Trial

Trial Information

Current as of February 05, 2025

Recruiting

Keywords

Hematologic Malignancy Adoptive Cellular Therapy Palliative Care Intervention Lymphoma Leukemia Multiple Myeloma Palliative Care

ClinConnect Summary

This clinical trial is looking at how palliative care, specifically a program called PEACE, can help improve the quality of life for patients with blood cancers like lymphoma, leukemia, or multiple myeloma who are undergoing a treatment called adoptive cellular therapy (ACT). The researchers want to see if adding this supportive care to standard cancer treatment makes a difference in how patients feel and cope during their therapy. About 90 people will participate, and after an initial phase, they will be assigned to either receive palliative care along with their usual treatment or just the usual treatment alone.

To be eligible for this study, participants must be 18 years or older, diagnosed with a blood cancer, and receiving a specific type of therapy at Massachusetts General Hospital. They should also be able to complete surveys in English or with help from an interpreter. However, individuals with significant cognitive issues or those already receiving palliative care cannot join the study. If you participate, you can expect to be involved for up to two years, during which your experiences and quality of life will be closely monitored. This study is currently recruiting participants and aims to provide valuable insights into the benefits of palliative care for patients undergoing these challenging treatments.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Age 18 years or older.
  • • Ability to complete surveys in English or with assistance of an interpreter.
  • • Diagnosis of a hematologic malignancy.
  • • Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product.
  • Exclusion Criteria:
  • • Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment.
  • • Already receiving palliative care (PC).

Trial Officials

Patrick C Johnson, MD

Principal Investigator

Massachusetts General Hospital

About Massachusetts General Hospital

Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.

Locations

Boston, Massachusetts, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials